IGUAZIO
Iguazio , the data science platform for real time machine learning applications, today announced that it has raised $24M of funding. The round was led by INCapital Ventures , with participation from existing and new investors, including Pitango , Verizon Ventures , Magma Venture Partners , Samsung SDS , Kensington Capital Partners , Plaza Ventures and Silverton Capital Ventures. The funds will be used by Iguazio to accelerate its growth and expand the reach of its data science platform to new global markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005301/en/
The demand for AI applications is on the rise. According to Gartner, AI augmentation alone will create $2.9 trillion of business value in 2021. However, there are still many challenges in deploying AI solutions in an effective and scalable way. An estimated 87% of data science models which have shown great promise in the lab never make it to production. This is due to the challenges of transforming a great AI model, which is functional in lab conditions, to a fully operational AI application that can deliver business impact at scale and in real time. Iguazio solves this problem and brings data science to life for enterprises worldwide.
The Iguazio data science platform helps data scientists create real-time AI applications while working within the familiar machine learning stack they know and love. The platform has been deployed by enterprises spanning a variety of verticals, including financial services and telecommunications. It is being used for a multitude of real-time use cases, such as self-healing networks, ride-hailing optimization, logistics optimization, and real-time recommendations. By way of example, Iguazio announced today that Payoneer , the global digital payment platform, has deployed the platform to predict and prevent fraud with real-time machine learning.
“Iguazio’s unique technology facilitates the data science creation process from start to finish, enabling enterprises to deploy AI applications that create real business impact,” said Tom Kennedy, Chairman of Kensington Capital Partners. “With the opportunities we are seeing for machine learning technology and the global success stories emerging from this high-tech nation, Iguazio represents a great first investment for Kensington in an Israeli company.”
“This is a pivotal time for AI. Our platform helps data scientists push the limits of their real-time AI applications and see their impact in real business environments,” said Asaf Somekh, co-founder and CEO of Iguazio. “With support from INCapital, Kensington Capital Partners, and our other investors, we are ready to expand our international team and reach our ambitious goals.”
About Iguazio
The Iguazio Data Science Platform enables enterprises to develop, deploy and manage AI applications at scale. With Iguazio, companies can run AI projects in real time, deploy them anywhere; multi-cloud, on-prem or edge, and bring to life their most ambitious data-driven strategies. Enterprises spanning a wide range of verticals, including financial services, manufacturing, telecoms and gaming, use Iguazio to create business impact through a multitude of real-time use cases. Iguazio is backed by top financial and strategic investors including Samsung , Verizon , Bosch , CME Group , and Dell . The company is led by serial entrepreneurs and a diverse team of innovators in the USA, UK, Singapore and Israel. Find out more on www.iguazio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200127005301/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom